Literature DB >> 2745259

In-vitro activities of temafloxacin, tosufloxacin (A-61827) and five other fluoroquinolone agents.

A L Barry1, R N Jones.   

Abstract

Tosufloxacin (A-61827) is the tosylate salt of A-60969 (T-3262). Temafloxacin (A-62254) is the hydrochloride salt of A-63004. Both compounds were tested against 945 aerobic bacterial isolates and their in-vitro activities were compared to those of five other fluoroquinolones. Ciprofloxacin and tosufloxacin were similar in their activity against the Enterobacteriaceae and Pseudomonas species. Temafloxacin and ofloxacin were similar in their activity against the Gram-negative bacilli. Strains that were susceptible to ciprofloxacin were also susceptible to ofloxacin, temafloxacin and tosufloxacin. Against nalidixic acid-resistant enteric bacilli, the potency of all seven fluoroquinolones was compromised. Enoxacin and fleroxacin were the least active drugs against Gram-positive species. Tosufloxacin was particularly active against the Gram-positive species; ciprofloxacin, difloxacin and temafloxacin were less active.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2745259     DOI: 10.1093/jac/23.4.527

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  27 in total

1.  Spontaneously occurring staphylococcal mutants resistant to clinically achievable concentrations of ciprofloxacin and temafloxacin.

Authors:  A L Barry; M A Pfaller; P C Fuchs
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-03       Impact factor: 3.267

2.  Effects of 2 quinolone antibacterials, temafloxacin and enoxacin, on theophylline pharmacokinetics.

Authors:  F Sörgel; G Mahr; G R Granneman; U Stephan; P Nickel; P Muth
Journal:  Clin Pharmacokinet       Date:  1992       Impact factor: 6.447

3.  Activity of temafloxacin against respiratory pathogens.

Authors:  R N Swanson; D J Hardy; D T Chu; N L Shipkowitz; J J Clement
Journal:  Antimicrob Agents Chemother       Date:  1991-03       Impact factor: 5.191

4.  Pharmacokinetics of temafloxacin in humans after single oral doses.

Authors:  G R Granneman; P Carpentier; P J Morrison; A G Pernet
Journal:  Antimicrob Agents Chemother       Date:  1991-03       Impact factor: 5.191

5.  Activity of new quinolones against ciprofloxacin-resistant staphylococci.

Authors:  G J Forstall; C C Knapp; J A Washington
Journal:  Antimicrob Agents Chemother       Date:  1991-08       Impact factor: 5.191

6.  Comparative in vitro activity of WIN 57273, a new fluoroquinolone antimicrobial agent.

Authors:  G M Eliopoulos; K Klimm; L B Rice; M J Ferraro; R C Moellering
Journal:  Antimicrob Agents Chemother       Date:  1990-06       Impact factor: 5.191

Review 7.  Current perspectives on glycopeptide resistance.

Authors:  N Woodford; A P Johnson; D Morrison; D C Speller
Journal:  Clin Microbiol Rev       Date:  1995-10       Impact factor: 26.132

8.  Temafloxacin pharmacokinetics in subjects with normal and impaired renal function.

Authors:  G R Granneman; R Braeckman; J Kraut; S Shupien; J C Craft
Journal:  Antimicrob Agents Chemother       Date:  1991-11       Impact factor: 5.191

Review 9.  Susceptibility of enterococci and epidemiology of enterococcal infection in the 1980s.

Authors:  R C George; A H Uttley
Journal:  Epidemiol Infect       Date:  1989-12       Impact factor: 2.451

10.  Species identification and antibiotic susceptibility testing of enterococci isolated from hospitalized patients.

Authors:  J W Gray; D Stewart; S J Pedler
Journal:  Antimicrob Agents Chemother       Date:  1991-09       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.